| |
| HCC |Abstract Library |
 |
| |
| The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors. |
| Abstract Details |
 |
|
| |
| |
| |
|
|
| |
Expanding the immunotherapy roadmap for hepatocellular carcinoma |
|
|
|
|
| |
Cancer Cell. 2022 Mar 14;40(3):252-254. doi: 10.1016/j.ccell.2022.02.017.
Marina Baretti 1, Amy K Kim 2, Robert A Anders 3
|
| |
|
|
| |
Author information
- Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
- Division of Gastroenterology and Hepatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: rander54@jhmi.edu.
Abstract
In a recent Lancet Oncology article, Yau et al. report the CheckMate 459 trial results. This is the first phase III trial comparing the single-agent anti-programmed death protein 1 (PD-1) therapy nivolumab to the tyrosine kinase inhibitor sorafenib for treatment-naive patients with advanced hepatocellular carcinoma.
|
|
|
|
| |
| |
|
| |
|
|
|
|
|
